In elderly patients with hepatitis C virus (HCV) genotype-1 infection, combination ombitasvir/paritaprevir/ritonavir is highly effective, according to study results published in Annals of Hepatology.
The results also indicated that tolerability should be monitored in this patient population when discontinuing or changing medications in order to avoid drug interactions.
The study included 70 participants from 6 locations in Japan with HCV genotype 1b (n=70); 50 of the participants were aged >65. Participants were treated with oral ombitasvir/paritaprevir/ritonavir once daily for 12 weeks. The primary end point was the percentage of elderly participants who achieved sustained virologic response 12 weeks after treatment completion. The researchers also recorded adverse events in order to assess drug safety and tolerability.
The sustained virologic response at 12 weeks post-treatment in the elderly participants was 94% (n=47) compared with 100% of younger participants, but this did not represent a significant difference (P =.153). Adverse events were observed in 23.3% (n=16) of participants.
After performing multivariate analysis, the researchers found that changing or discontinuing concomitant drugs due to drug interactions occurred independently of risk factors for adverse events associated with this drug combination (P =.015; odds ratio 15.9; 95% CI, 1.79-148).
“Especially, elderly patients who suffer from more than one disease, eg, hypertension and chronic kidney dysfunction, need to consider not only the treatment conditions of each disease but also the possibility of other related diseases,” the researchers wrote. “Therefore, it is necessary to carefully examine the effects of each drug, as in the present study, which proved the efficacy and tolerability of [ombitasvir/paritaprevir/ritonavir] for elderly patients.”
Uojima H, Kobayashi S, Hidaka H, et al. Efficacy and tolerability of ombitasvir/paritaprevir/ritonavir in HCV genotype-1 infected elderly Japanese patients. Ann Hepat. 2018;18(1):109-115.